Drug intelligence / Profile preview

anti-cd19 interleukin-10 + interleukin-15 chimeric antigen receptor natural killer cells

Development stage: Phase 1
Lead developer: Second Affiliated Hospital of Zhejiang University School of Medicine
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Anti-CD19 Interleukin-10 + Interleukin-15 Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells is an investigational cell-based biologic therapy. It consists of cord blood-derived natural killer (NK) cells that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-lymphocyte antigen CD19. Additionally, the cells are modified to co-express the cytokines interleukin-10 (IL-10) and interleukin-15 (IL-15). This design aims to utilize IL-15 to enhance the persistence and cytotoxic function of the NK cells, while IL-10 is intended to modulate the inflammatory environment. The therapy is primarily being developed to deplete pathogenic B cells in patients with refractory or relapsed autoimmune diseases, such as systemic lupus erythematosus and systemic sclerosis.

Other names: anti-cd19 interleukin-10 + interleukin-15 chimeric antigen receptor natural killer cellsAnti-CD19 IL-10/IL15 CAR-NK cells

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on anti-cd19 interleukin-10 + interleukin-15 chimeric antigen receptor natural killer cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-cd19 interleukin-10 + interleukin-15 chimeric antigen receptor natural killer cells.

Explore the full profile